Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Res Pract Thromb Haemost ; 8(3): 102388, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38651093

RESUMO

Background: Mortality due to immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains significant. Predicting mortality risk may potentially help individualize treatment. The French Thrombotic Microangiopathy (TMA) Reference Score has not been externally validated in the United States. Recent advances in machine learning technology can help analyze large numbers of variables with complex interactions for the development of prediction models. Objectives: To validate the French TMA Reference Score in the United States Thrombotic Microangiopathy (USTMA) iTTP database and subsequently develop a novel mortality prediction tool, the USTMA TTP Mortality Index. Methods: We analyzed variables available at the time of initial presentation, including demographics, symptoms, and laboratory findings. We developed our model using gradient boosting machine, a machine learning ensemble method based on classification trees, implemented in the R package gbm. Results: In our cohort (n = 419), the French score predicted mortality with an area under the receiver operating characteristic curve of 0.63 (95% CI: 0.50-0.77), sensitivity of 0.35, and specificity of 0.84. Our gradient boosting machine model selected 8 variables to predict acute mortality with a cross-validated area under the receiver operating characteristic curve of 0.77 (95% CI: 0.71-0.82). The 2 cutoffs corresponded to sensitivities of 0.64 and 0.50 and specificities of 0.76 and 0.87, respectively. Conclusion: The USTMA Mortality Index was acceptable for predicting mortality due to acute iTTP in the USTMA registry, but not sensitive enough to rule out death. Identifying patients at high risk of iTTP-related mortality may help individualize care and ultimately improve iTTP survival outcomes. Further studies are needed to provide external validation. Our model is one of many recent examples where machine learning models may show promise in clinical prediction tools in healthcare.

3.
Blood ; 140(12): 1335-1344, 2022 09 22.
Artigo em Inglês | MEDLINE | ID: mdl-35797471

RESUMO

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. When all episodes of iTTP were included, Black race was associated with shorter RFS (hazard ratio [HR], 1.60; 95% CI, 1.16-2.21); the addition of rituximab to corticosteroids improved RFS in White (HR, 0.37; 95% CI, 0.18-0.73) but not Black patients (HR, 0.96; 95% CI, 0.71-1.31). In de novo iTTP, rituximab delayed relapse, but Black patients had shorter RFS than White patients, regardless of treatment. In relapsed iTTP, rituximab significantly improved RFS in White but not Black patients. Race affects overall relapse risk and response to rituximab in iTTP. Black patients may require closer monitoring, earlier retreatment, and alternative immunosuppression after rituximab treatment. How race, racism, and social determinants of health contribute to the disparity in relapse risk in iTTP deserves further study.


Assuntos
Púrpura Trombocitopênica Trombótica , Proteína ADAMTS13 , Corticosteroides , Humanos , Púrpura Trombocitopênica Trombótica/terapia , Recidiva , Rituximab/uso terapêutico
5.
Clin J Gastroenterol ; 13(5): 728-731, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32524464

RESUMO

CASE REPORT: A 45-year-old female presented to the surgery emergency department with complaints of pain in the whole abdomen, vomiting and non-passage of flatus and stools for the past one day. Physical examination revealed tachycardia with a normal blood pressure. The abdomen showed diffuse tenderness and guarding and bowel sounds were absent. After appropriate fluid resuscitation, the patient underwent a non-contrast computed tomography, which showed intra-abdominal free air. She was then prepared for exploratory laparotomy. Intraoperatively, three jejunal diverticula were identified at the mesenteric side, with perforation of the distal two. Segmental resection of the jejunum, including three diverticula, with primary end-to-end anastomosis was performed. Histopathology report confirmed the diagnosis of jejunal diverticula. CONCLUSION: Jejunal diverticula are extremely rare and are usually asymptomatic. However, such presentation warrants their inclusion under the differential diagnosis of acute abdomen, albeit lower down the order. Isolated jejunal diverticular perforation is a rare complication and may present as a surprise intraoperative finding to the operating surgeon.


Assuntos
Abdome Agudo , Divertículo , Perfuração Intestinal , Doenças do Jejuno , Abdome Agudo/etiologia , Divertículo/diagnóstico , Divertículo/diagnóstico por imagem , Feminino , Humanos , Perfuração Intestinal/etiologia , Perfuração Intestinal/cirurgia , Doenças do Jejuno/diagnóstico , Doenças do Jejuno/diagnóstico por imagem , Jejuno/cirurgia , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...